On the stock market since 2024, it operates in the world of health and science. It has 19,200 employees. Now — the numbers.
This is an established company with proven profits.
Average growth of 7% a year over the last 4 years. Every year shown ended in profit.
The gap is $1.6B. In times of high interest rates, a gap like that can squeeze a company.
We compared this company with its own sector across five subjects.
A score of 50 means class average.
Profit power and business quality lead the class.
Clearly below the class average.
The price looks reasonable next to what the company earns.
There is growth, but not at top-of-the-class tempo.
Clearly below the class average.
Financial Strength: The cash-and-debt balance is thin; the buffer for hard times is slim.
Price Momentum: The stock has lagged the market in recent months; investor interest is weak right now.
angles, checked one by one.
The 3 that stand out are on screen; the rest came back neutral.
The council scores out of 10; report-card grades are out of 100.
The stock trades 48% below its peak. The market has trimmed its expectations for the company.
Over the last 12 months, company executives reported 23 buys and 12 sells. Management buying with its own money is usually read as a good sign.
The average analyst price target is $13.33 — 27% above today’s price.
The balance sheet offers little cushion against a rough stretch. Report-card grade: 26/100.
Buyers haven’t stepped back in yet; the price hasn’t found its footing. Report-card grade: 47/100. For a turnaround signal, the stock first needs to close the gap with the market.
On our five-subject report card, ARDT sits near the top of the class. A high grade doesn’t mean “guaranteed win” — it means “the evidence looks strong for now.”
The takeaway: ARDT is an established business that has proven its profits for years. The real debate here isn’t the price — it’s whether the company can keep up this pace.
The total grade weighs these five subjects against the sector — it isn’t a simple average of the five.